- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 10: Can Clinical Pathways Be Personalized?
According to Blase Polite, MD, MPP, pathways are well-designed to allow personalized medicine.
Surabhi Dangi-Garimella, PhD, then asked the panelists whether clinical pathways can prevent patients from receiving more personalized care.
Blase Polite, MD, MPP, said that “personalized medicine” is another one of those tricky terms that are thrown around, but may have different definitions for everyone. In general, however, personalized medicine is about the genetic makeup of a tumor.
In this sense, pathways are beautifully suited for personalized medicine according to Dr Polite. “I can look and know that you have a mutation that makes it much more likely that you’re going to respond to drug X or drug …It sort of forces you to say have you looked for all these personalized things. Then we’ll drive you to treatment.”
Pathways allow the physician to go off-pathway when it no longer makes sense for the patient, but one should also avoid extremes. “If I am 100% on pathway, you should be worried about me. You should also be worried if I am 80% off pathway. There is some sweet spot in there that says I am taking into account clinical situations, and I’m still using the patient in front of me, the art of medicine, everything that I know about their social situation, their opinion, etc,” Dr Polite explained.
Dr Polite hopes that in using pathways responsibly, physicians will not be penalized too severely for still practicing the art of medicine.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
